Pneumovax 23

The final marketed vaccine formulation of PCV13 contains capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria CRM₁₉₇ carrier protein and adsorbed on AlPO₄ (0.125 mg aluminum). Each 0.5-mL dose contains 2.2 µg of polysaccharides of each serotype, except for serotype 6B polysaccharides, which contain 4.4 µg. Excipients include sodium chloride, succinic acid, polysorbate 80, and water for injection. PCV13 formulations used in study A (South Africa) with and without AlPO₄ did not contain polysorbate 80.⁷ (link)
PPSV23 (Pneumovax® 23; Merck & Co., Inc., Whitehouse Station, NJ) contains capsular polysaccharides from serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F. Each 0.5-mL dose contains 25 µg of each polysaccharide type. Excipients include 0.25% phenol as a preservative, sodium chloride, and water.
Study vaccine was administered into the deltoid muscle.

V114 is a 15-valent PCV containing capsular polysaccharide from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F, 23F, 22F, and 33F, all conjugated to CRM₁₉₇ carrier protein and adjuvanted with 125 μg aluminum phosphate. PCV13 (Prevnar 13; Wyeth LLC, marketed by Pfizer, New York, New York, USA) is a 13-valent PCV containing capsular polysaccharide from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, all conjugated to CRM₁₉₇ carrier protein and adjuvanted with 125 μg aluminum phosphate. PPSV23 (PNEUMOVAX23; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, USA) is an unadjuvanted 23-valent pneumococcal polysaccharide vaccine. Each dose contains 25 μg of pneumococcal capsular polysaccharide from serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
V114 and PCV13 were supplied as sterile suspensions and PPSV23 was supplied as a sterile solution. All vaccines were supplied in prefilled syringes and stored at 2–8°C. They were all administered intramuscularly as 0.5 ml doses.

Thirty six patients were included within the study between May 2009 and June 2012. Of these patients, 34 had medically refractory chronic ITP, one had hereditary spherocytosis, and one had autoimmune hemolytic anemia. Informed consent was obtained prior to the procedure. The patients consisted of 19 women and 17 men with a mean age of 54.5 (range 22-66 years). Preoperative platelet counts were under 50.000/mm³ in all patients (range 1.000-48.500). Pneumococcus (Pneumovax 23, Merck & Co Inc., Whitehouse Station, NJ, USA) and Haemophilus influenza type B (Hiberix, GlaxoSmithKline) vaccines were administered two weeks before the operations. The risk of operative bleeding was reduced with IV prednisolone (1 mg/kg) and intravenous IgG (1 g/kg) medication. TUMP-LS was performed in 19 patients and standard LS in 17 patients by the same surgeon. Two groups of patients were compared retrospectively by means of operation time, intra- and postoperative blood loss, perioperative complications, packed red cell and platelet requirements, length of hospitalization, visual analog scale (VAS) pain scores and patient satisfaction (Likert Scale). Umbilical incisions and blood tests of patients were checked on postoperative day 10, 1^st , 3^rd , and 6^th month. Additionally, ultrasonography (USG) was performed in sixth month and first year of follow-up to assess if there was any incisional hernia.

Mice were i.v. or i.p. immunized with 5 µg TNP-Ficoll, 5 µg TNP-LPS (LGC Biosearch Technologies), 2.87 µg Pneumovax 23 (Merck), or 50 µg NP-OVA supplemented with alum (LGC Biosearch Technologies). Mice were also i.v. infected with 2 × 10⁷ SP (CPS-14) or i.n. infected with 100 PFU mouse-adapted human influenza virus A/PR/8/34 (PR8). In some experiments, SP was treated with mitomycin to inhibit bacterial proliferation. Lung tissue was processed to determine viral titers by plaque-forming assays.